BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37656935)

  • 21. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
    Speir RW; Calaway AC; Einhorn LH; Foster RS; Cary C
    Urol Oncol; 2020 Aug; 38(8):687.e19-687.e23. PubMed ID: 32448503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
    Djaladat H; Nichols C; Daneshmand S
    Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
    Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
    J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection.
    Nestler T; Paffenholz P; Pfister D; Schoch J; Nini A; Hiester A; Albers P; Heidenreich A
    J Urol; 2024 Mar; 211(3):426-435. PubMed ID: 38085711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group.
    Gerdtsson A; Thor A; Grenabo Bergdahl A; Almås B; Håkansson U; Törnblom M; Negaard HFS; Glimelius I; Halvorsen D; Karlsdóttir Á; Sagstuen Haugnes H; Engen Andreassen K; Melsen Larsen S; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Ståhl O; Kjellman A
    Eur Urol Oncol; 2022 Apr; 5(2):235-243. PubMed ID: 33750683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
    Nguyen CT; Stephenson AJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Sheinfeld J
    Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
    Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
    J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.
    Nayan M; Jewett MA; Sweet J; Anson-Cartwright L; Bedard PL; Moore M; Chung P; Warde P; Hamilton RJ
    J Urol; 2015 Aug; 194(2):386-91. PubMed ID: 25823792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
    Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
    Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Tal R; Sheinfeld J
    J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
    Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
    Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ejaculatory function in stage T1 nonseminomatous germ cell tumors: retroperitoneal lymph node dissection versus surveillance--a decision analysis.
    Langenstroer P; Rosen MA; Griebling TL; Thrasher JB
    J Urol; 2002 Oct; 168(4 Pt 1):1396-401. PubMed ID: 12352401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor.
    Nason GJ; Jewett MAS; Bostrom PJ; Goldberg H; Hansen AR; Bedard PL; Sturgeon J; Warde P; Chung P; Anson-Cartwright L; Sweet J; Atenafu EG; O'Malley M; Hamilton RJ
    Eur Urol Oncol; 2021 Apr; 4(2):289-296. PubMed ID: 32907779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.